AUA 2016: Efficacy and Tolerability of Mirabegron in Multiple Sclerosis: A Prospective Analysis - Session Highlights

San Diego, CA USA ( Temitope Rude presented data on mirabegron use in Multiple Sclerosis patients. The authors prospectively enrolled Multiple Sclerosis patients who were not taking antimuscarinic medications (or had undergone 3 weeks of washout) and surveyed these patients at baseline and at 6 weeks.

The data was analyzed for 13 patients at 6 weeks, and although a small sample, there was a significant change in overactive bladder syndrome symptoms as well as constipation-related bowel function. Dr. Rude also mentioned that the difference in bowel symptom scores on the Patient Assessment of Constipation symptoms exceeded the minimum clinically important difference for the survey. There were no reports of increased blood pressure, urinary retention, dry mouth or cognitive impairment.

The authors concluded that these findings are encouraging for improvements in bowel and bladder symptoms using mirabegron in Multiple Sclerosis.


Presented By: Temitope Rude, MD


Written By: Lindsey Cassini Cox M.D. Clinical Assistant Professor, Female Pelvic Medicine & Reconstructive Surgery, MUSC Health, Medical University of South Carolina, at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA